GlobalRPh Renal Dosing Masterv6.8
Product-specific reference

Dorzolamide 2% ophthalmic solution (Trusopt)

Local official-label summarySource retrieved 2026-10-02See the evidence for this drug2 sources available - open source summaries, references and comparisons

dorzolamide / Trusopt / dorzolamide ophthalmic

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Before use: Dorzolamide 2% ophthalmic solution (Trusopt)

Historical label retained as a dated renal restriction; current marketed-product reconciliation is pending.

Before applying: Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Evidence for this qualification

Selected source reconciliation only; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Product / population
Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).
Renal measure
Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Source revision
12/2020 (historical supplement)
Retrieved
2026-10-02 (not the revision date)

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Renal guidance and important limits

Limits that apply to these rows

Topical administration can produce systemic exposure and sulfonamide reactions. Concomitant oral carbonic-anhydrase inhibitors are not recommended because effects may be additive.

Historical FDA 2020 supplement: current exact marketed-product labeling remains to be reconciled. This entry is not a claim of current-label approval.

Dorzolamide 2% ophthalmic solution (Trusopt) - selected renal instructions
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied, and parent drug/metabolite are predominantly renally eliminated.
Other renal bands / renal replacement therapyNo additional renal dose schedule is established by this selected summary; absence of a row is not evidence of safety.
Read the retained text before reformatting
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied, and parent drug/metabolite are predominantly renally eliminated.
Other renal bands / renal replacement therapyNo additional renal dose schedule is established by this selected summary; absence of a row is not evidence of safety.

Topical administration can produce systemic exposure and sulfonamide reactions. Concomitant oral carbonic-anhydrase inhibitors are not recommended because effects may be additive.

Historical FDA 2020 supplement: current exact marketed-product labeling remains to be reconciled. This entry is not a claim of current-label approval.

Source revision: 12/2020 (historical supplement) | Retrieved: 2026-10-02. Retrieval date is not the revision date.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020408s052lbl.pdf

Scope: Selected renal sections summarized locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.8.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v6.8

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Retrieved: 2026-10-02
Source revision: 12/2020 (historical supplement)

Renal measure: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.

Read this dated source finding
Rxlist

Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Retrieved: 2026-10-02
Source revision: 12/2020

Renal measure: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.

Read this dated source finding
See all retained evidence sources
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Source retrieved 2026-10-02

No dialysis regimen established in selected content

Read the source and its limits

Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Source retrieved 2026-10-02

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Renal method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Retrieved: 2026-10-02

Read local renal resultOpen original reference
GlobalRPh RX List

Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Renal method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Retrieved: 2026-10-02

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Dorzolamide 2% ophthalmic solution (Trusopt)

Historical label retained as a dated renal restriction; current marketed-product reconciliation is pending.

How to use this: Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sectionsDorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Selected source reconciliation only; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.

Renal guidance and important limitsRead this complete source summary
Rxlist source

Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.

Renal guidance and important limitsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDorzolamide 2% ophthalmic solution (Trusopt) - selected label sectionsDorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020408s052lbl.pdf

Exact product and population

Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

RDM68-dorzolamide-trusopt-eec2f99a09 · Source section: Selected primary product label: indications / formulationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sections

Open original reference

Open / share this exact local source

FDA / historical TRUSOPT label supplement · Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Renal method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Source date: 12/2020 (historical supplement)
Retrieved: 2026-10-02

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

Topical administration can produce systemic exposure and sulfonamide reactions. Concomitant oral carbonic-anhydrase inhibitors are not recommended because effects may be additive.

Historical FDA 2020 supplement: current exact marketed-product labeling remains to be reconciled. This entry is not a claim of current-label approval.

Dorzolamide 2% ophthalmic solution (Trusopt) - selected renal instructions
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied, and parent drug/metabolite are predominantly renally eliminated.
Other renal bands / renal replacement therapyNo additional renal dose schedule is established by this selected summary; absence of a row is not evidence of safety.
Read the retained text before reformatting
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied, and parent drug/metabolite are predominantly renally eliminated.
Other renal bands / renal replacement therapyNo additional renal dose schedule is established by this selected summary; absence of a row is not evidence of safety.

Topical administration can produce systemic exposure and sulfonamide reactions. Concomitant oral carbonic-anhydrase inhibitors are not recommended because effects may be additive.

Historical FDA 2020 supplement: current exact marketed-product labeling remains to be reconciled. This entry is not a claim of current-label approval.

RDM68-dorzolamide-trusopt-f2954c6307 · Source locator: Sections 2, 3, 5.1, 7.1 and 8.6

Source-specific limits

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020408s052lbl.pdf
Retrieved
2026-10-02
Renal-function method
Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Source date/version
12/2020 (historical supplement)
Hash meaning
Local authored summary; not source HTML/XML/PDF bytes
Local summary SHA-256
f2954c6307f6a12b4cb3b5ac71ea5b001cf5fa750fdf1378b1fabcbfd1155f1a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summary

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).

Renal method: Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Source date: 12/2020
Retrieved: 2026-10-02

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

The December 2020 mirror does not recommend single-ingredient dorzolamide when CrCl is below 30 mL/min. It notes systemic absorption despite topical dosing and renal elimination of the drug/metabolite. This evidence must not be automatically applied to dorzolamide/timolol combination drops.

RDM68-dorzolamide-trusopt-49f18b35b6 · Source locator: Named RX renal impairment, dosage and renal-warning sections

Source-specific limits

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Source identity and provenance
Source family
product_label
Source
https://globalrph.com/rx-list/trusopt-drug/
Retrieved
2026-10-02
Renal-function method
Creatinine clearance (CrCl), mL/min; severe-impairment restriction applies despite ophthalmic administration.
Source date/version
12/2020
Hash meaning
Local authored summary; not source HTML/XML/PDF bytes
Local summary SHA-256
49f18b35b6f358afc40858d2112f9d0d171a8876c35a7e8f1d0ae9d4d7104640

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020408s052lbl.pdf
Source retrieval
2026-10-02. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
eec2f99a09363da02c5c0dd0b7009a8694abd1b84a391e79681fdc7057169182
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report